Ex-Organon Executive Meghan Rivera Joins Mayne Pharma Board

Ex-Organon Executive Meghan Rivera Joins Mayne Pharma Board

S
Shivangi
Jun 26, 2026 2:21 PM IST
Category News

Synopsis

Mayne Pharma has appointed healthcare executive Meghan Rivera to its board, bringing experience from Organon, Akili Interactive and ViiV Healthcare.

Mayne Pharma has announced the appointment of U.S. pharmaceutical executive Meghan Rivera as Non-Executive Director, effective June 26.

Strengthening U.S. Expertise

Rivera has more than 25 years of experience in the U.S. pharmaceutical industry. She currently works as Vice President and Global Commercial Lead at ViiV Healthcare.

Previously, she held roles as U.S. Market President at Organon & Co, chief marketing officer at Akili Interactive and senior vice president of Women’s Health at AMAG Pharmaceuticals. She has a background in women's health, medical technology, and biosimilars and branded product launches.

Supporting Growth Strategy

Mayne Pharma chair, Frank Condella welcomed Rivera and said he consistently demonstrated the experience and skill set to build and transform biopharmaceutical businesses throughout his career, starting with a deep commitment towards women’s health, which was aligned with Mayne’s strategy.

Rivera stated that she looks forward to helping to unlock Mayne Pharma’s commercial opportunity with the portfolio of products in women’s health and dermatology, as well as its ​DistributeRx platform to reach patients directly.

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on dermatology and women’s health in the United States Beyond solid-released pharmaceutical products, it also exclusively contracts development and manufacturing services globally but has over 40 years of experience in oral drug delivery technologies.

Source: Capital Brief


Follow Inspirepreneur Magazine for daily global business news.

S
Written by Shivangi

At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.